CL2024000222A1 - Esquema de dosificación de agonistas de los receptores de glp1/glucagón de acción prolongada - Google Patents

Esquema de dosificación de agonistas de los receptores de glp1/glucagón de acción prolongada

Info

Publication number
CL2024000222A1
CL2024000222A1 CL2024000222A CL2024000222A CL2024000222A1 CL 2024000222 A1 CL2024000222 A1 CL 2024000222A1 CL 2024000222 A CL2024000222 A CL 2024000222A CL 2024000222 A CL2024000222 A CL 2024000222A CL 2024000222 A1 CL2024000222 A1 CL 2024000222A1
Authority
CL
Chile
Prior art keywords
long
receptor agonists
glucagon receptor
dosage regimen
glp1
Prior art date
Application number
CL2024000222A
Other languages
English (en)
Spanish (es)
Inventor
Desch Michael
Magdalena Hennige Anita
Isabel Schoelch Corinna
Thamer Claus
Per Martin Bergstrand Jan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2024000222A1 publication Critical patent/CL2024000222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2024000222A 2021-07-30 2024-01-25 Esquema de dosificación de agonistas de los receptores de glp1/glucagón de acción prolongada CL2024000222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21188741 2021-07-30

Publications (1)

Publication Number Publication Date
CL2024000222A1 true CL2024000222A1 (es) 2024-08-02

Family

ID=77155646

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000222A CL2024000222A1 (es) 2021-07-30 2024-01-25 Esquema de dosificación de agonistas de los receptores de glp1/glucagón de acción prolongada

Country Status (10)

Country Link
US (1) US20250262279A1 (https=)
EP (1) EP4376871A1 (https=)
JP (1) JP2024529452A (https=)
KR (1) KR20240043778A (https=)
CN (1) CN117677395A (https=)
AU (1) AU2022320922A1 (https=)
CA (1) CA3226846A1 (https=)
CL (1) CL2024000222A1 (https=)
MX (1) MX2024001276A (https=)
WO (1) WO2023006923A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2019060660A1 (en) * 2017-09-25 2019-03-28 Merck Sharp & Dohme Corp. CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Also Published As

Publication number Publication date
WO2023006923A1 (en) 2023-02-02
CA3226846A1 (en) 2023-02-02
EP4376871A1 (en) 2024-06-05
AU2022320922A1 (en) 2024-01-18
JP2024529452A (ja) 2024-08-06
MX2024001276A (es) 2024-02-15
KR20240043778A (ko) 2024-04-03
US20250262279A1 (en) 2025-08-21
CN117677395A (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
CL2024000222A1 (es) Esquema de dosificación de agonistas de los receptores de glp1/glucagón de acción prolongada
CO2023008866A2 (es) Coagonistas de los receptores de glp-1 y amilina
CL2020002033A1 (es) Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
DOP2023000023A (es) Agonistas del glp-1 heterocíclicos
CL2023002731A1 (es) Análogos, sales, composiciones y métodos de uso de la psilocibina
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX2021000792A (es) Metodo de uso de un coagonista de gip/glp1 para la diabetes.
MX2019001318A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2017003208A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
JOP20210153B1 (ar) ماسيتينتان لعلاج ارتفاع ضغط الدم الشرياني الرئوي
EA201990501A1 (ru) Фармацевтическая композиция
WO2021081193A8 (en) Methods of administration of il-2 receptor agonists
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
GEAP202416618A (en) Quinoline derivatives as modulators of mas-related g-protein receptor x2 and related products
CL2025001811A1 (es) Péptido agonista dual de glp-1 y glucagón con estabilidad biológica mejorada; y composición farmacéutica.
BR112023027321A2 (pt) Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo
JOP20250233A1 (ar) مُنشِّط ثلاثي جديد لمستقبلاتglp-1/gip/ جلوكاجون، وتركيب صيدلاني للوقاية من أو علاج السمنة الذي يحتوي عليه
CO2023008101A2 (es) Formulaciones de péptidos terapéuticos
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
CO2025003888A2 (es) Nuevos derivados pirazina-carboxamida sustituidos
PE20130529A1 (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
CL2024000429A1 (es) Contra enfermedades inflamatorias intestinales que involucra la disrupción del ensamblaje de heterómeros ccr9:drd5
ES178896A1 (es) UN MONTAJE PARA SINCRONIZAR EL GENERADOR DE TENSIoN EN DIENTES DE SIERRA DE IMAGEN EN UN RECEPTOR